Publication from our members: ‘A life in a day’ simulation experience: perceptions of oncology nurses and pharmacy staff

‘A life in a day’ simulation experience: perceptions of oncology nurses and pharmacy staff

Rachel Ehibhatiomhan, Emma Foreman, Lisa Barrott, Jessica Shek & Shereen Nabhani-Gebara

Background

Due to an increase in patient numbers, more cancer patients are being reviewed by non-medical healthcare professionals (HCPs), and it is essential that they can empathise with patients and care for them holistically. ‘A Life in a Day’ is a role reversal simulation (RRS) which demonstrates the challenges, choices and impacts that cancer patients face every day, facilitated by a Smartphone application (app). This study focused on renal cell carcinoma (RCC) and was designed to evaluate the impact of RRS on participants from the British Oncology Pharmacy Association (BOPA) and the UK Oncology Nursing Society (UKONS), and identify any changes made to clinical practice as a result.

Method

A survey was conducted via the app before and after the experience. Individual semi-structured interviews were conducted with participants over Microsoft Teams.

Results

Data from the survey showed that after the experience 97% of all participants strongly agreed that they ‘feel empathy for RCC patients’ and 90% strongly agreed that they ‘feel inspired to place patients at the centre of their work’. There were 5 themes extrapolated from the qualitative data: Holistic understanding of Patients, Reflections on Practice, Changes in Practice, Outreach to Colleagues, Education & Training.

Conclusion

Participants reported an increase in empathy for their patients which inspired them to make changes to their practice. This involved being more holistic in their care and taking on more responsibility. They recommended use of RRS for HCP training and continued professional development. They also suggested incorporation of RRS into the pharmacy undergraduate curriculum.

 

Read the article in full here:  https://bmcnurs.biomedcentral.com/articles/10.1186/s12912-022-01086-8

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article